Insmed (INSM)
Commercializes rare pulmonary disease medicines while developing pulmonary, antibody and gene therapies.
$119.70
vs last close−1.12 (−0.93%)
Something off on this page? Send us feedback.
Next report
Oct 29, 26
in 36 days
EPS estimate
−$0.39
Revenue estimate
$501.2M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Oct '25Feb '26May '26Aug '26Oct '26
Reported−$1.32−$1.42−$1.70−$1.75−$1.54−$0.76−$0.06Pending
Estimate−$1.17−$1.34−$1.30−$1.33−$1.07−$0.96−$0.67−$0.39
Surprise−12.8%−6.0%−30.8%−31.6%−43.9%+21.1%+91.1%—
RevenueReportedEstimate
Feb '25May '25Aug '25Oct '25Feb '26May '26Aug '26Oct '26
Reported$104.4M$92.8M$107.4M$142.3M$263.8M$306.0M$425.5MPending
Estimate$102.1M$91.5M$104.1M$115.4M$231.2M$300.8M$395.5M$501.2M
Surprise+2.3%+1.5%+3.2%+23.3%+14.1%+1.7%+7.6%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | $1.01 | — | — |
| Sep 2028 | $0.68 | — | — |
| Jun 2028 | $0.60 | — | — |
| Mar 2028 | $0.56 | — | — |
| Dec 2027 | $0.42 | — | — |
| Sep 2027 | $0.28 | — | — |
| Jun 2027 | $0.14 | — | — |
| Mar 2027 | −$0.15 | — | — |
| Dec 2026 | −$0.34 | — | — |
| Oct 2026 | −$0.39 | — | — |
| Aug 2026 | −$0.67 | −$0.06 | +91.1% |
| May 2026 | −$0.96 | −$0.76 | +21.1% |
| Feb 2026 | −$1.07 | −$1.54 | −43.9% |
| Oct 2025 | −$1.33 | −$1.75 | −31.6% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Oct 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Oct 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Oct 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Oct 2020 | |||
| Aug 2020 | |||
| Apr 2020 | |||
| Feb 2020 | |||
| Oct 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Oct 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | $1.01 | — | — | $944.9M | — | — | — |
| Sep 2028 | $0.68 | — | — | $976.9M | — | — | — |
| Jun 2028 | $0.60 | — | — | $916.3M | — | — | — |
| Mar 2028 | $0.56 | — | — | $771.3M | — | — | — |
| Dec 2027 | $0.42 | — | — | $799.3M | — | — | — |
| Sep 2027 | $0.28 | — | — | $737.5M | — | — | — |
| Jun 2027 | $0.14 | — | — | $672.3M | — | — | — |
| Mar 2027 | −$0.15 | — | — | $583.7M | — | — | — |
| Dec 2026 | −$0.34 | — | — | $571.7M | — | — | — |
| Oct 29, 2026 | −$0.39 | — | — | $501.2M | — | — | — |
| Aug 6, 2026 | −$0.67 | −$0.06 | +91.1% | $395.5M | $425.5M | +7.6% | +33.9% |
| May 7, 2026 | −$0.96 | −$0.76 | +21.1% | $300.8M | $306.0M | +1.7% | −23.4% |
| Feb 19, 2026 | −$1.07 | −$1.54 | −43.9% | $231.2M | $263.8M | +14.1% | +6.5% |
| Oct 30, 2025 | −$1.33 | −$1.75 | −31.6% | $115.4M | $142.3M | +23.3% | +16.3% |
| Aug 7, 2025 | |||||||
| May 8, 2025 | |||||||
| Feb 20, 2025 | |||||||
| Oct 31, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 9, 2024 | |||||||
| Feb 22, 2024 | |||||||
| Oct 26, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 4, 2023 | |||||||
| Feb 23, 2023 | |||||||
| Oct 27, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 5, 2022 | |||||||
| Feb 17, 2022 | |||||||
| Oct 28, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 6, 2021 | |||||||
| Feb 25, 2021 | |||||||
| Oct 29, 2020 | |||||||
| Aug 6, 2020 | |||||||
| Apr 30, 2020 | |||||||
| Feb 25, 2020 | |||||||
| Oct 30, 2019 | |||||||
| Aug 1, 2019 | |||||||
| May 7, 2019 | |||||||
| Feb 22, 2019 | |||||||
| Oct 30, 2018 | |||||||
| Aug 2, 2018 | |||||||
| May 2, 2018 | |||||||
| Feb 23, 2018 | |||||||
| Nov 2, 2017 | |||||||
| Aug 3, 2017 | |||||||
| May 3, 2017 | |||||||
| Feb 23, 2017 | |||||||
| Nov 3, 2016 | |||||||
| Aug 4, 2016 | |||||||
| May 5, 2016 | |||||||
| Feb 25, 2016 | |||||||
| Nov 6, 2015 | |||||||
| Aug 6, 2015 |